pregnancy specific beta-1-glycoprotein 10, pseudogeneGenealiases: []
Q-omics provides the consensus-scored PSG10P profile across patient tissues and cancer cell-line models. PSG10P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PSG10P is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, PSG10P RNA expression shows 9,435 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BRCA, and GBM as cancer lineages where PSG10P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSG10P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSG10P survival associations across molecular data types. PSG10P RNA expression shows survival associations in the most cancer types (19), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSG10P RNA expression–survival associations across cancer types. High PSG10P expression shows unfavorable associations in KIRC, MESO, DLBC and LUSC, but favorable associations in BLCA and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PSG10P RNA expression.
This table summarizes PSG10P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for PSG10P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSG10P shows lower tumor expression in BRCA and ESCA and higher tumor expression in HNSC, LUSC and LUAD. The BRCA box plot shows higher PSG10P RNA expression in normal versus tumor tissue (log2 FC = −0.033, t-test p = .043).
This table shows molecular features associated with PSG10P in patient tissues and cancer cell lines. In patient samples, PSG10P shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PSG10P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS.
